DexCom Inc

DXCMHealthcare

Sentinellis Health Score

10/10

Financially healthy

Market Cap

$25.8B

Revenue

$4.7B

P/E Ratio

28.7x

AI Summary

DexCom designs and sells wearable glucose sensors that continuously measure blood sugar levels and send real-time data to a smartphone or receiver [Yahoo Finance]. Their core products include the Dexcom G7 and G6 systems for intensive diabetes management, Stelo for adults with prediabetes and Type 2 diabetes who don't use insulin, and the newly launched Dexcom Flex for Type 2 patients using basal insulin or oral medications [Yahoo Finance]. The company sells directly to doctors, endocrinologists, and diabetes educators in the U.S. and internationally [Yahoo Finance].

DexCom is a medical device company that makes continuous glucose monitoring (CGM) systems—wearable sensors that let people with diabetes check their blood sugar levels 24/7 without finger pricks [Yahoo Finance]. The company just announced a major 10-year growth plan promising at least 10% annual revenue growth through 2030, along with a $1 billion share buyback program [Yahoo Finance]. With $4.7 billion in revenue, strong profitability, and recent product launches like Dexcom Flex in Germany, the company is expanding access to CGM technology beyond insulin-dependent patients [Yahoo Finance].

DexCom is financially very healthy with strong profitability, no net debt, and excellent cash generation.

Confidence8/10